Recombinant vaccines against bluetongue virus

• Published in: Virus Research
• Main Authors: Calvo Pinilla, Eva María, Castillo-Olivares, J., Jabbar, T., Ortego Alonso, Francisco Javier, De la Poza, F., Marín-López, A.
• Format: Article in Journal/Newspaper
• Language: English
• Published: Elsevier 2014
• Subjects: Bluetongue virus; Recombinant vaccines; DIVA; Heterotypic protection; Antarc*; Antarctica
• Online Access: https://hdl.handle.net/20.500.12792/5590; http://hdl.handle.net/10261/291405; https://doi.org/10.1016/j.virusres.2013.11.013

Bluetongue (BT) is a hemorrhagic disease of ruminants caused by bluetongue virus (BTV), the prototype member of the genus Orbivirus within the family Reoviridae and is transmitted via biting midges of the genus Culicoides. BTV can be found on all continents except Antarctica, and up to 26 immunologically distinct BTV serotypes have been identified. Live attenuated and inactivated BTV vaccines have been used over the years with different degrees of success. The multiple outbreaks of BTV in Mediterranean Europe in the last two decades and the incursion of BTV-8 in Northern Europe in 2008 has re-stimulated the interest to develop improved vaccination strategies against BTV. In particular, safer, cross-reactive, more efficacious vaccines with differential diagnostic capability have been pursued by multiple BTV research groups and vaccine manufacturers. A wide variety of recombinant BTV vaccine prototypes have been investigated, ranging from baculovirus-expressed sub-unit vaccines to the use of live viral vectors. This article gives a brief overview of all these modern approaches to develop vaccines against BTV including some recent unpublished data. © 2013 The Authors.